Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: A cross-sectional study of 275 hyperlipidemic women

Metabolism: Clinical and Experimental

Volumn 50, Issue 3, 2001, Pages 360-365

  Glueck, Charles J ^a   Wang, Ping ^a   Fontaine, Robert N ^a   Sieve Smith, Luann ^a   Lang, James E ^a  

^a JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTHROMBIN; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; HETEROZYGOSITY; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT CONTRAINDICATION;

EID: 0035087879     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.21020     Document Type: Article

References (29)

1. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
2. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
3. Commentary on the women's health initiative
4. Design of the women's health initiative clinical trial and observational study. The women's health initiative study group
5. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the Factor V Leiden mutation (resistance to activated protein C)
6. Heterozygosity for the Leiden mutation of the Factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens
7. Exogenous estrogen may exacerbate thrombophilia, impair bone healing, and contribute to development of chronic facial pain
8. Sensitivity to activated protein C: Influence of contraceptives and sex
9. Coagulation activation following estrogen administration to postmenopausal women
10. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
11. Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives
12. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
13. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease
14. The heterozygous 20210 A G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease
15. The factor II G20210A and factor V1691 A gene transitions and coronary heart disease
16. The prothrombin 20210A allele and the Factor V Leiden are associated with venous thrombosis but not with early coronary artery disease
17. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and Factor V Leiden in coronary artery disease: High Factor V clotting activity is an independent risk factor for myocardial infarction
18. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
19. Lipoprotein metabolism in the elderly
20. Thrombophilia and hypofibrinolysis: Reversible pathogenetic etiologies of osteonecrosis in adults and in children (Legg-Perthes disease). AOA International Symposium on Osteonecrosis
21. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic women
22. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer
23. The relationship of mutations in the methylenetetrahydrofolate reductase, prothrombin, and plasminogen activator inhibitor-1 genes to plasma levels of homocysteine, prothrombin, and plasminogen activator inhibitor-1 levels in children and adults
24. The Factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation
25. Arterial thromboembolic events in women with the Factor V Leiden mutation
26. Factor V Leiden, prothrombin 20210 gene variant, and risk of myocardial infarction
27. C677T MTHFR mutation and Factor V Leiden mutation in patients with TIA/minor stroke: A case-control study
28. Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke